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ABSTRACT
INTRODUCTION: Pulmonary thromboembolism the third most common medical emergency with mortality 
two-phase vascular response occurs. Lung ischaemia-reperfusion injury. Lung reperfusion damage is believed 
to cause cellular damage and apoptosis. The aim of the present study was to evaluate the levels of fetuin-A, 
albumin, and apoptosis biomarkers (Apaf-1, sFas, and sFasL) among pulmonary thromboembolic patients.
MATERIAL AND METHODS: Blood samples were collected from 45 volunteer patients and 40 healthy control 
volunteers. Human apoptosis biomarkers (Apaf-1, sFas, sFasL, and caspase-9) and fetuin-A values were 
measured by ELISA device. Student’s t-test or Mann-Whitney U test were used for continuous variables, 
and categorical variables were compared with the chi-square test to assess the significance of intergroup 
differences. The mean values of apoptosis biomarkers and acute phase reactants between dead and survival 
patients were also compared.
RESULTS: While the apoptosis mean values of Apaf-1, sFas, sFasL, and caspase-9 for the control group were 
0.12 ± 0.01, 332.1 ± 28.0, 130.4 ± 34.6, and 74.3 ± 2.6, for the patient group they were 0.14 ± 0.02, 
509.1 ± 67.6, 139.9 ± 23.7, and 79.4 ± 2.8, respectively. The group differences were significant for all the 
biomarkers (p = 0.01, p = 0.001, p = 0.19, and p = 0.01, respectively). The negative acute phase fetu-
in-A and albumin levels decreased significantly in the patient groups (p = 0.01 and p = 0.01, respectively).
CONCLUSİONS: Intrinsic and extrinsic apoptosis pathways are stimulated during pulmonary embolism, and 
negative acute phase reactants are decreased. There was a correlation with the mortality and Apaf-1, sFas, 
caspase-9, fetuin, and albumin levels.
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INTRODUCTION
Pulmonary thromboembolism (PE) is the third most 
common medical emergency with mortality after 
cardiac and cerebrovascular diseases [1]. In PE at 
least two-phase vascular response, ischaemia, and 
reperfusion occurs. Lung ischaemia-reperfusion in-
jury is associated with the alveolar-capillary barrier, 
and especially with alveolar epithelial cell damage. 
Thus, pulmonary vascular permeability is increased 
in relation to the formation of reactive oxygen inter-
mediates, endothelial cell injury, cytokine activation, 
neutrophil activation, and inflammation response. 
Lung reperfusion damage is believed to cause cellu-
lar damage and apoptosis [2–4].
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Apoptosis, known as type I death, was defined 
in the 1970s. It is accepted that this process is im-
portant primarily for tissue homeostasis [5]. De-
pending on the stimulus, the extrinsic and intrinsic 
pathways are the main pathways. The intrinsic path-
way is activated by intracellular stressors, growth 
factor deprivation, and oxidative stress. Induced B 
cell lymphoma-2 family members (Bax, Bak, Bcl-2, 
and Bcl-xL) by the stressor factors increases the mi-
tochondrial outer membrane permeabilisation and 
cytochrome c release into the cytoplasm. This process 
ends with the complex occurred by cysteine protease, 
caspase-9 adapter protein, and apoptotic protease-ac-
tivating factor-1 (Apaf-1), known as “apoptosome”. 
Apoptosome then takes procaspase-9, located at the 
N-terminus of both Apaf-1 and procaspase-9, which 
induces caspase-3 and cell death [6–8].
Extrinsic apoptosis starts with the activation of 
the death receptor family proteins: CD95 (Fas/Apo1), 
TNF-related apoptosis-inducing ligand (TRAIL) recep-
tors, and TNF receptors. This interaction is followed 
by death-related death domain (FADD) protein and 
procaspase-8/10, the death-causing signal complex 
that activates caspase-3, -6, and -7. The activated 
effector caspases induce cell death or activate the 
intrinsic pathway, which also causes cell death [9].
The Fas protein is the best-identified member 
of the 24-member TNF receptor family. The Fas cell 
receptor that controls cell death in the immune 
system is found on cytotoxic T cells and natural killer 
cells. The Fas protein binds to its receptor at the cell 
surface and provides receptor trimerisation. Activat-
ed receptors combine with the FADD receptor mol-
ecule. In this way, by stimulating the region near the 
carboxyl-terminus of the Fas receptor, procaspases 
are activated and apoptosis begins. As well as Fas 
and TNF-α, the TRAIL and TRAIL receptors can also 
induce apoptosis in a similar way [10]. 
Fetuin-A, also known as human alpha-2-HS-gly-
coprotein, is mainly derived from the liver paren-
chymal cells in adults. It has anti-apoptotic and 
anti-inflammatory activity. While the anti-apoptotic 
activity is enabled by inhibiting the caspases-3, -8, 
and -9 subunits that are the main cornerstones in in-
trinsic and extrinsic apoptosis pathways, the anti-in-
flammatory is made by macrophage deactivation, 
antifibrotic activity [11–13].
The aim of the present study was to evaluate the 
levels of fetuin-A, albumin, and apoptosis biomark-
ers among PE patients. We hypothesised that while 
the apoptotic biomarkers would increase due to 
the increased oxidative stress, fetuin-A and albumin 
would be decreased due to its utilisation as a pro-
tective mediator for the anti-inflammatory effect. 
MATERIAL AND METHODS
This prospective case-control study includes pa-
tients 45 (26 male and 19 female) with acute PE, 
who were admitted to the Emergency Department 
of Cumhuriyet University Hospital from 2018 July 
to 2019 May. The diagnosis of PE was made with 
contrast-positive thoracic computed tomography. 
The control group consisted of 40 patients (24 fe-
male, 16 male).
Patients with previous weight management 
strategies (such as caloric restriction), weight loss 
surgeries, haematological malignancy, chronic liver 
disease, diabetes mellitus, or with acute or chronic 
inflammatory disease were excluded from the study. 
The participants were informed about the study 
and their written approval was obtained. The study 
protocol was approved by the institutional Eth-
ics Committee of the Sivas Cumhuriyet University 
(2108-06/17), and consent was obtained from all 
patients or their relatives.
No human rights were violated during this study, 
and the study was in accordance with the Declara-
tion of Helsinki.
Blood samples were collected from 45 volun-
teer patients with pulmonary embolism, who did 
not receive any treatment before admission at Sivas 
Cumhuriyet University Medical Faculty Emergency 
Department. A control group was formed from 
40 volunteers who were similar to the patient group 
according to age and gender. 
Approximately 5 mL of venous blood samples 
were taken from the patient and control groups 
and added to biochemistry tubes. After 5–10 min at 
room temperature, the samples were centrifuged at 
4000 rpm. The supernatant (serum) formed on top 
was transferred to Eppendorf tubes and stored at 
–80°C until the tests were studied. 
Plasma fetuin-A levels were measured using 
a human fetuin-A enzyme-linked immunosorbent 
assay measurements with Elisa kit for each sample. 
(ELISA kit Cat no: EK-067-52, lot no: 603894; Phoe-
nix Pharmaceuticals, Belmont, CA, USA). 
Human apoptosis biomarkers (Apaf-1, sFas, sFasL, 
and caspase 9) were also measured by enzyme-linked 
immunosorbent assay method with the Wuhan Fine 
Biological Technology Co. Hubei China kit.
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Data were analysed with SPSS software ver-
sion 22.0 for Windows (IBM Corp., New-York, 
USA). Continuous variables were presented as 
mean ± standard deviation as appropriate, and cat-
egorical variables as numbers (%). Student’s t-test 
or Mann-Whitney U test was used for continuous 
variables, and categorical variables were compared 
with the chi-square test to assess the significance of 
intergroup differences
RESULTS
The average age of the control and patient group 
was 66.33 ± 17.5 and 68.17 ± 16.9, respectively. 
The control group comprised 24 males and 16 fe-
males, and the patient group consisted of 26 males 
and 19 females. There was no difference according 
to gender distribution (χ2 = 0.04, p > 0.05).
We analysed the mean values of apoptosis and 
acute phase reactant biomarkers between the con-
trol and patient groups. While apoptosis biomarkers 
(Apaf-1, sFas, caspase-9) in the patient group were 
significantly increased, negative acute phase reac-
tants (fetuin-A and albumin) were decreased signif-
icantly (p = 0.01, p = 0,001, p = 0.01, p = 0.01, 
and p = 0.01, respectively). Only the difference of 
sFasL between the two groups was not significant 
(p = 0.19) (Tab. 1)
We also analysed the apoptosis biomarkers, al-
bumin, and fetuin levels among the in-patients who 
died or were discharged from the hospital. The apop-
tosis biomarkers (Apaf-1, sFas, caspase-9) mean levels 
were significantly higher, whereas albumin and fetuin 
mean levels were significantly lower in the patient 
group who died (p = 0.006, p < 0.001, p = 0.01, 
p = 0.0039, and p = 0.002, respectively) (Tab. 2), 
which showed us that these biomarkers can be used 
for prognostication, whereas the sFasL levels did not 
show any difference between the groups (p = 0.817) 
DISCUSSION
The extent of pulmonary cell death, infarct size, is 
the most important predictor of survival and long-
term outcome in patients with PE. After PE cell death 
can occur due to oedema, inflammation, neutrophil 
migration, and intraparenchymal haemorrhage. All 
of the states can be defined as necrosis and apopto-
sis. While necrosis is the irreversible cell death form 
due to the loss of cell membrane integrity and ion 
pump damage, apoptosis is defined as programmed 
cell death [14].
By electron microscopy, apoptotic cell death is 
morphologically characterised by overall cellular 
condensation, shrinkage, and plasma membrane 
blebbing. Nuclear changes are characterised by 
chromatin margination and nuclear condensation 
followed by segmentation and DNA fragmentation. 
Finally, the apoptotic cell is broken up into smaller 
membrane-bound apoptotic bodies that are usually 
Table 1. Apoptosis and biochemical biomarkers between control and patient groups
Parameters
Control group (n = 40) Patient group (n = 45) P
Mean ± SD Mean ± SD Student t-test
WBC (× 103/mm3) 7.5 ± 2.0 14.6 ± 2.8 0.01
Glucose (mg/dL) 103.3 ± 18.0 127.4 ± 59.1 0.02
BUN (mg/dL) 17.2 ± 5.9 23.1 ± 5.7 0.01
Creatinine (mg/dL) 0.8 ± 0.2 1.0 ± 0.4 0.01
Calcium (mg/dL) 9.1 ± 0.5 8.8 ± 0.8 0.04
C-reactive protein 7.2 ± 2.9 59.7 ± 23.7 0.01
Albumin (mg/dL) 4.4 ± 0.5 3.4 ± 0.7 0.01
Apaf-1 (ng/mL) 0.12 ± 0.01 0.14 ± 0.02 0.01
sFas (pg/mL) 332.1 ± 28.0 509.1 ± 67.6 0.001
sFasL (pg/mL) 130.4 ± 34.6 139.9 ± 23.7 0.19
Fetuin-A (mg/dL) 11.8 ± 1.8 7.4 ± 1.5 0.01
Caspase-9 (ng/mL) 74.3 ± 2.6 79.4 ± 2.8 0.01
Apaf-1 — apoptotic protease-activating factor-1; BUN — blood urea nitrogen; sFasL — soluble Fas ligand; WBC — white blood cell; SD — standard deviation
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phagocytosed by macrophages. An important mor-
phologic distinction from necrosis lies in the fact 
that apoptotic cell death lacks inflammation [15].
Apoptosis is a clinical state that is induced by 
many pathways. Pro-oxidants, ionising radiation, 
protein synthesis inhibitors, apoptotic or physiolog-
ic stimulants, and pro-apoptotic genes are some of 
the pathways. Cell death occurs either by necrosis 
or apoptosis during an increased level of oxidative 
stress [16].
In PE pulmonary vascular circulation is occluded 
and this impairs gas exchange and circulation, which 
increases reactive oxygen species. İncreased ROS 
induces lipid peroxidation, inflammatory cytokines 
released after the migration of macrophage, and 
neutrophils. Also, there is accelerated apoptotic cell 
death [17].
Arnalich et al. [18] analysed the plasma levels of 
mitochondrial and nuclear DNA in patients with pul-
monary embolism and compared them with plasma 
heart-type fatty acid-binding protein and troponin I 
biomarkers. The plasma mt-DNA and n-DNA con-
centrations were higher in the massive pulmonary 
embolism group, compared with the sub-massive 
and control groups. Also, the plasma levels were in-
creased for mt-DNA 2.3-fold and for n-DNA 1.9-fold 
among the non-surviving patients, compared with 
the survivors [18].
This study reveals that cell death is correlated with 
pulmonary embolism severity. Cell death in PE occurs 
either by necrosis or apoptosis. İn our study we have 
determined that the intrinsic and extrinsic apoptosis 
biomarkers are increased. The increased rate of DNA 
concentrations can be related to apoptosis. 
FasL expression is regulated by oxidants that are 
generated in different clinicopathological states like 
PE-related inflammation and ischaemia/reperfusion 
injury [19]. Suzuki et al. [20] investigated the rela-
tionship between oxidative stress and sFasl levels in 
human umbilical vein endothelial cells. The oxidative 
stress was provided by exposing endothelial cells to 
nontoxic concentrations (1–100 µM) H2O2 and cig-
arette smoke extracts (0.5–1%). The H2O2 increased 
the FasL level significantly to 0.1–0.3 ng/mL ac-
cording to the exposure level, which was deter-
mined by cell-monolayer-based spectrofluorimetry 
and flow cytometry. Also, FasL increased significantly 
after cigarette smoke extracts [20]. İt is known that 
Fas/FasL is increased to an inflammatory response. 
Adly et al. [21] analysed the sFas and sFasL levels in 
sickle cell disease. They compared the levels of sFas 
and sFasL among the patient and control group. 
sFas and sFas/sFasL ratio were significantly higher 
in SCD patients compared with the control group 
(p < 0.001), whereas the sFasL was significantly 
lower in patients (p = 0.022). In conclusion of the 
study, they revealed that the apoptosis biomarkers 
were significantly higher in patients with pulmo-
nary hypertension or nephropathy [21]. Cardinal 
et al. [22] researched apoptotic sFas levels among 
patients with chest pain for the diagnostic accuracy 
of acute coronary syndromes. sFas baseline levels 
increased the diagnostic accuracy for acute coronary 
syndromes. The sFas and sFasL levels were signifi-
cantly higher in the patient group as a sign for the 
activated apoptosis pathway in pulmonary throm-
boembolism. 
In the intrinsic pathway after the activation of 
Bax proteins, cytochrome c and Apaf-1 are released 
from the mitochondria. The release of Apaf-1 induc-
es caspase-9 and the subsequent caspase cascade. 
The result is the apoptosis of the cell. Forgiarini et 
al. [23] determined that an ischaemia period longer 
than 45 minutes increased the caspase cascade ac-
tivated the apoptosis. Wang et al. [24] confirmed 
that caspase-9 and Apaf levels were increased and 
Table 2. Apoptosis biomarkers between dead and survival patients:
Parameters
Survival patients (n = 38) Non-survival patients (n = 7) P
Mean ± SD Mean ± SD Mann-Whitney U
Apaf-1 (ng/mL) 0.13 ± 0.02 0.16 ± 0.02 0.006
sFas (pg/mL) 491.5 ± 58.5 595.2 ± 36.7 < 0.001
sFasL (pg/mL) 140.7 ± 26.3 138.3 ± 5.8 0.817
Caspase-9 (ng/mL) 79.0 ± 2.8 81.9 ± 1.3 0.01
Fetuin-A (mg/dL) 7.7 ± 1.4 5.9 ± 0.7 0.002
Albumin (mg/dL) 3.6 ± 0.8 2.9 ± 0.2 0.039
Apaf-1 — apoptotic protease-activating factor-1; sFasL — soluble Fas ligand; SD — standard deviation
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apoptosis occurred in acute myocardial infarction. 
They exhibited a new compound (ZYZ-488) with car-
dioprotective properties by reducing the apoptosis 
rate. They examined the apoptosis biomarker levels, 
caspase-9, and Apaf-1 by treating the mice with 
ZYZ-488. Apoptosis biomarker levels induced by is-
chaemia in myocardial infarction decreased after the 
treatment, and the ejection fraction was better [24].
In our study, the Apaf-1 and caspase-9 levels were 
increased significantly among the patient group, 
which explains the increased apoptosis rate (Tab. 1)
Fetuin-A is known as a protein with pro- and 
anti-inflammatory features. İt induces the cytokines 
expression and macrophages as a positive acute-
phase protein. Whereas in a disease like sepsis, trau-
ma, cerebral ischaemic diseases acts as a negative 
acute-phase protein [25, 26].
Peng Ma and Yi-Chao Feng [27] investigated 
the fetuin-A serum levels in inflammatory bowel 
diseases among 139 patients with Crohn’s disease, 
114 patients with ulcerative colitis, and 46 healthy 
persons. They revealed that fetuin-A levels were sig-
nificantly lower in the people with active inflammato-
ry bowel diseases when compared with healthy and 
nonactive inflammatory bowel diseases [27]. Minas 
et al. [11] analysed the correlation of fetuin-A and 
chronic pulmonary disease severity, a progressive 
inflammatory disease. They determined that lower 
levels of fetuin-A were positively correlated with pul-
monary function tests and disease severity [11].
An inflammatory process takes part in PE is also 
after the pulmonary arteries are occluded that has 
decreased the fetuin-A levels in our study. Also, the 
mean fetuin-A levels were significantly lower in the 
patients who died. These results established that fe-
tuin can be used as a prognostic marker in PE cases.
Albumin is the main source for plasma thiols. Par-
lak et al. [28] evaluated the relationship between dy-
namic thiol/disulphide levels in pulmonary embolism 
patients and healthy groups. They demonstrated that 
the plasma thiol/disulphide rate was decreased in 
the patients with pulmonary embolism, which may 
indicate that the albumin level is also reduced [28].
Hayıroğlu et al. [29] evaluated the prognostic nu-
tritional index in PE. According to the classification, 
prognostic nutritional index patients in tertile 1 was 
8.1 times higher. Albumin levels in tertile 1 were also 
significantly lower than in tertile 3. As a result, they 
demonstrated that serum albumin-based prognostic 
nutritional index was an independent prognostic 
factor for mortality in patients with PE [29]. Our 
results for negative acute-phase reactant albumin 
were similar to these studies, and there was a signif-
icant decrease in serum albumin level for non-sur-
vival patients, which indicated it as a prognostic 
biomarker for PE disease.
Strengths and limitations
The strength of this study is that it is the first study to 
represent a significant association between apoptosis 
biomarkers, fetuin-A, albumin, and PE. The results 
indicate that this biomarker can be used for progno-
sis determination. Nevertheless, there are some lim-
itations to our current study. First, all of our patient 
group was recruited from a single-centre large sample 
with a limited patient number, and hence a multicen-
tre study with a large number of patients is needed. 
CONCLUSIONS
Pulmonary thromboembolism is not only a disease 
whose progression is dependent on necrosis and 
inflammation; intrinsic and extrinsic apoptosis path-
ways are stimulated during the PE process, and 
negative acute phase reactants levels are decreased. 
These biomarkers can be used as auxiliary diagnos-
tic and prognostic biomarkers. 
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